title: [Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology].
abstract: Seven patients with gynecologic infections were treated with the new carbapenem class of antibiotic, imipenem/cilastatin sodium (MK-0787/MK-0791) at a dose level of 500 mg/500 mg or 250 mg/250 mg administered intravenously every 12 hours for 5 days. The results obtained were as follows. Clinical effects of MK-0787/MK-0791 were analyzed in 7 patients, including 1 case with pelvic peritonitis, 2 cases with endometritis, adnexitis and pelvic peritonitis, abdominal abscess, vaginal cuff infection and parametritis, and pyometra. Excellent clinical response was seen in 3 cases and good response in 4 cases. No side effect nor abnormal finding in clinical laboratory values was seen in all patients.
authors.forename: K
authors.initials: K
authors.lastname: Okamura
authors.forename: M
authors.initials: M
authors.lastname: Nakakuki
authors.forename: K
authors.initials: K
authors.lastname: Yamada
authors.forename: N
authors.initials: N
authors.lastname: Ikeno
authors.forename: M
authors.initials: M
authors.lastname: Watanabe
authors.forename: K
authors.initials: K
authors.lastname: Takahashi
authors.forename: K
authors.initials: K
authors.lastname: Muraguchi
authors.forename: A
authors.initials: A
authors.lastname: Saito
authors.forename: T
authors.initials: T
authors.lastname: Wakisaka
authors.forename: H
authors.initials: H
authors.lastname: Murai
mesh_terms: D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D015377:Cilastatin; D003521:Cyclopropanes / Q000008:administration & dosage* / Q000627:therapeutic use; D004150:Dipeptidases / Q000037:antagonists & inhibitors*; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D015378:Imipenem; D007262:Infusions, Intravenous; D008875:Middle Aged; D013845:Thienamycins / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D003521:Cyclopropanes; D004338:Drug Combinations; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem; D004150:Dipeptidases